Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus

Bone Marrow Transplantation volume 48, pages 544–550 (2013)Cite this article

Subjects

Abstract

Our previous data have revealed that proteinuria, antinuclear antibodies and anti-dsDNA antibodies in refractory systemic lupus erythematosus (SLE) reduced after MSC infusion. This study focused on the roles of mesenchymal SCT (MSCT) in SLE patients with refractory cytopenia. Thirty-five SLE patients with refractory cytopenia were enrolled in a MSCT trial. Hematological changes of pre- and post-transplantation were evaluated. Mechanisms for MSCT effects focused on the analysis of percentage of regulatory T cells (Treg) and Th17. The results showed that in 35 SLE patients, 20 patients had leukopenia, 24 with anemia or thrombocytopenia. The average follow-up period after MSCT was 21 months (range 6–45 months). Significant improvements in blood cell count were found after MSCT for most patients, in parallel with the decline of disease activity. Clinical remission was accompanied by increased Treg and decreased Th17. Two patients died of uncontrolled disease recurrence after infection, whereas no adverse events related to transplantation was observed. The result suggested that MSCT could reverse hematological aberration in SLE patients with refractory cytopenia, which might be associated with reconstitution of Treg and Th17. Longer follow-up and clinical larger-scale controlled study, as well as the exact mechanism exploration, will need further investigations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Petri M . Systemic lupus erythematosus: 2006 update. J Clin Rheumatol 2006; 12: 37–40.

    Article  Google Scholar 

  2. Pontikoglou C, Deschaseaux F, Sensebé L, Papadaki HA . Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev 2001; 7: 569–589.

    Article  Google Scholar 

  3. Nauta AJ, Fibbe WE . Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499–3506.

    Article  CAS  Google Scholar 

  4. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120–4126.

    Article  CAS  Google Scholar 

  5. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M . Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74–85.

    Article  Google Scholar 

  6. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S et al. (2009) Mesenchymal stem cell transplantation reverses multi-organ dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421–1432.

    Article  CAS  Google Scholar 

  7. Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008; 5: 417–424.

    Article  Google Scholar 

  8. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2467–2475.

    Article  CAS  Google Scholar 

  9. Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010; 69: 1423–1429.

    Article  Google Scholar 

  10. Smith EL, Shmerling RH . The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus 1999; 8: 586–595.

    Article  CAS  Google Scholar 

  11. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–317.

    Article  CAS  Google Scholar 

  12. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579–1586.

    Article  CAS  Google Scholar 

  13. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem cell transplantation. Blood 2007; 110: 2764–2767.

    Article  CAS  Google Scholar 

  14. Christopeit M, Schendel M, Föll J, Müller LP, Keysser G, Behre G . Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008; 22: 1062–1064.

    Article  CAS  Google Scholar 

  15. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yañez AJ, Conget PA . Systemic administration of multipotent mesenchymal stromal cells revert hyperglycaemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 2008; 14: 631–640.

    Article  CAS  Google Scholar 

  16. Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG . Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 2006; 65: 144–148.

    Article  CAS  Google Scholar 

  17. Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X et al. fficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis 2011; 70: 1285–1288.

    Article  Google Scholar 

  18. Roffe C, Cahill MR, Samanta A, Bricknell S, Durrant ST . Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism? Br J Rheumatol 1991; 30: 301–304.

    Article  CAS  Google Scholar 

  19. Sumimoto S, Kawai M, Kasajima Y, Hamamoto T . Aplastic anemia associated with systemic lupus erythematosus. Am J Hematol 1991; 38: 329–331.

    Article  CAS  Google Scholar 

  20. Sakaguchi S, Powrie F . Emerging challenges in regulatory T cell function and biology. Science 2007; 317: 627–629.

    Article  CAS  Google Scholar 

  21. Nalbandian A, Crispin JC, Tsokos GC . Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009; 157: 209–215.

    Article  CAS  Google Scholar 

  22. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1472–1483.

    Article  Google Scholar 

Download references

Acknowledgements

Dr Li and Professor Sun’s work was supported by the National Natural Science Foundation of China (No. 81172847, 30972736); Jiangsu Province Natural Science Foundation (BK2009034); Major International (Regional) Joint Research Project (81120108021), Jiangsu Province Kejiao Xingwei Program.

Author information

Author notes

  1. X Li and D Wang: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Immunology and Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

    X Li, D Wang, J Liang, H Zhang & L Sun

Authors
  1. X Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Sun.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, X., Wang, D., Liang, J. et al. Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplant 48, 544–550 (2013). https://doi.org/10.1038/bmt.2012.184

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.184

Keywords

This article is cited by

Search

Advanced search

Quick links